If you made any changes in Pure these will be visible here soon.

Research Output

  • 22 Journal article
  • 17 Conference abstract in journal
  • 2 Poster
  • 1 Conference article in Journal
Filter
Journal article
2020

Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies

Vergote, I. B., Lund, B., Peen, U., Umajuridze, Z., Mau-Sorensen, M., Kranich, A., Van Nieuwenhuysen, E., Haslund, C., Nottrup, T., Han, S. N., Concin, N., Unger, T. J., Chai, Y., Au, N., Rashal, T., Joshi, A., Crochiere, M., Landesman, Y., Shah, J., Shacham, S. & 2 others, Kauffman, M. & Mirza, M. R., Feb 2020, In : Gynecologic Oncology. 156, 2, p. 308-314 7 p.

Research output: Contribution to journalJournal articleResearchpeer-review

4 Citations (Scopus)
2019

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

González-Martín, A., Pothuri, B., Vergote, I., DePont Christensen, R., Graybill, W., Mirza, M. R., McCormick, C., Lorusso, D., Hoskins, P., Freyer, G., Baumann, K., Jardon, K., Redondo, A., Moore, R. G., Vulsteke, C., O'Cearbhaill, R. E., Lund, B., Backes, F., Barretina-Ginesta, P., Haggerty, A. F. & 11 others, Rubio-Pérez, M. J., Shahin, M. S., Mangili, G., Bradley, W. H., Bruchim, I., Sun, K., Malinowska, I. A., Li, Y., Gupta, D., Monk, B. J. & PRIMA/ENGOT-OV26/GOG-3012 Investigators, 19 Dec 2019, In : The New England Journal of Medicine. 381, 25, p. 2391-2402 12 p.

Research output: Contribution to journalJournal articleResearchpeer-review

151 Citations (Scopus)

Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial

Del Campo, J. M., Matulonis, U. A., Malander, S., Provencher, D., Mahner, S., Follana, P., Waters, J., Berek, J. S., Woie, K., Oza, A. M., Canzler, U., Gil-Martin, M., Lesoin, A., Monk, B. J., Lund, B., Gilbert, L., Wenham, R. M., Benigno, B., Arora, S., Hazard, S. J. & 1 others, Mirza, M. R., 10 Nov 2019, In : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 37, 32, p. 2968-2973 6 p.

Research output: Contribution to journalJournal articleResearchpeer-review

Open Access
File
15 Citations (Scopus)
10 Downloads (Pure)

Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial

Mirza, M. R., Åvall Lundqvist, E., Birrer, M. J., dePont Christensen, R., Nyvang, G-B., Malander, S., Anttila, M., Werner, T. L., Lund, B., Lindahl, G., Hietanen, S., Peen, U., Dimoula, M., Roed, H., Ør Knudsen, A., Staff, S., Krog Vistisen, A., Bjørge, L., Mäenpää, J. U., AVANOVA investigators & 1 others, Lund, B., Oct 2019, In : The Lancet. Oncology. 20, 10, p. 1409-1419 11 p.

Research output: Contribution to journalJournal articleResearchpeer-review

28 Citations (Scopus)
2018

Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial

Oza, A. M., Matulonis, U. A., Malander, S., Hudgens, S., Sehouli, J., Del Campo, J. M., Berton-Rigaud, D., Banerjee, S., Scambia, G., Berek, J. S., Lund, B., Tinker, A. V., Hilpert, F., Vázquez, I. P., D'Hondt, V., Benigno, B., Provencher, D., Buscema, J., Agarwal, S. & Mirza, M. R., 2018, In : The Lancet. Oncology. 19, 8, p. 1117-1125 9 p.

Research output: Contribution to journalJournal articleResearchpeer-review

34 Citations (Scopus)
2016

Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer

Dahl Steffensen, K., Waldstrøm, M., Brandslund, I., Lund, B., Mejer Sørensen, S., Petzold, M. & Jakobsen, A., 2016, In : Oncology Letters. 11, 6, p. 3967-3974 8 p.

Research output: Contribution to journalJournal articleResearchpeer-review

Open Access
10 Citations (Scopus)

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

du Bois, A., Kristensen, G., Ray-Coquard, I., Reuss, A., Pignata, S., Colombo, N., Denison, U., Vergote, I., Del Campo, J. M., Ottevanger, P., Heubner, M., Minarik, T., Sevin, E., de Gregorio, N., Bidziński, M., Pfisterer, J., Malander, S., Hilpert, F., Mirza, M. R., Scambia, G. & 8 others, Meier, W., Nicoletto, M. O., Bjørge, L., Lortholary, A., Sailer, M. O., Merger, M., Harter, P. & AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium, Jan 2016, In : Lancet Oncology. 17, 1, p. 78-89 12 p.

Research output: Contribution to journalJournal articleResearchpeer-review

121 Citations (Scopus)
2015

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

Oza, A. M., Cook, A. D., Pfisterer, J., Embleton, A., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Park-Simon, T-W., Rustin, G., Joly, F., Mirza, M. R., Plante, M., Quinn, M. S., Poveda, A., Jayson, G. C., Stark, D., Swart, A. M. & 5 others, Farrelly, L., Kaplan, R., Parmar, M. K. B., Perren, T. J. & ICON7 trial investigators, Aug 2015, In : Lancet Oncology. 16, 8, p. 928-936 9 p.

Research output: Contribution to journalJournal articleResearchpeer-review

Open Access
File
330 Citations (Scopus)
176 Downloads (Pure)
2014

A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer

Wang, Y., Herrstedt, J., Havsteen, H., Christensen, R. D., Mirza, M. R., Lund, B., Maenpaa, J. & Kristensen, G., 2014, In : B M C Cancer. 2014, 14, 937.

Research output: Contribution to journalJournal articleResearchpeer-review

Open Access
5 Citations (Scopus)

Vellykket behandling af lokal avanceret, småcellet, neuroendokrint cervixkarcinom

Rasmussen, L. B., Lindegaard, J. C., Lund, B., Grove, A. & Fokdal, L. U., 2014, In : Ugeskrift for Laeger. 176, 2 p., V06140374.

Research output: Contribution to journalJournal articleResearchpeer-review

2013

Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: the PaLiDo study, a phase II nonrandomized multicenter study

Steffensen, K. D., Waldstrøm, M., Pallisgård, N., Lund, B., Bergfeldt, K., Wihl, J., Keldsen, N., Marth, C., Vergote, I. & Jakobsen, A., 1 Jan 2013, In : International Journal of Gynecological Cancer. 23, 1, p. 73-80 8 p.

Research output: Contribution to journalJournal articleResearchpeer-review

18 Citations (Scopus)

Primært malignt melanom i vagina

Translated title of the contribution: Primary malignant melanoma of the vaginaKahr, H. S., Mejlgaard, E. & Lund, B., 14 Jan 2013, In : Ugeskrift for Laeger. 175, 3, p. 133-4 2 p.

Research output: Contribution to journalJournal articleResearchpeer-review

3 Citations (Scopus)
2012

Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial

Brundage, M., Gropp, M., Mefti, F., Mann, M. K., Lund, B., Gebski, V., Wolfram, G., Reed, N., Pignata, S., Ferrero, A., Brown, J. C., Eisenhauer, E. & Pujade-Lauraine, E., Aug 2012, In : Annals of Oncology. 23, 8, p. 2020-7 8 p.

Research output: Contribution to journalJournal articleResearchpeer-review

29 Citations (Scopus)
2011

A phase 3 trial of bevacizumab in ovarian cancer

Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., du Bois, A., Sehouli, J., Kimmig, R., Stähle, A., Collinson, F., Essapen, S., Gourley, C., Lortholary, A., Selle, F., Mirza, M. R. & 7 others, Leminen, A., Plante, M., Stark, D., Qian, W., Parmar, M. K. B., Oza, A. M. & ICON7 Investigators, 29 Dec 2011, In : The New England Journal of Medicine. 365, 26, p. 2484-96 13 p.

Research output: Contribution to journalJournal articleResearchpeer-review

1260 Citations (Scopus)

Improved Classification of Epithelial Ovarian Cancer: Results of 3 Danish Cohorts

Steffensen, K. D., Waldstrom, M., Grove, A., Lund, B., Pallisgard, N. & Jakobsen, A., 16 Sep 2011, In : International Journal of Gynecological Cancer. 21, p. 1592-1600 9 p.

Research output: Contribution to journalJournal articleResearchpeer-review

30 Citations (Scopus)

Radiobiological impact of reduced margins and treatment technique for prostate cancer in terms of tumor control probability (TCP) and normal tissue complication probability (NTCP)

Jensen, I., Carl, J., Lund, B., Larsen, E. H. & Nielsen, J. N., 2011, In : Medical Dosimetry. 36, p. 130-7 8 p.

Research output: Contribution to journalJournal articleResearchpeer-review

10 Citations (Scopus)
2010

A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin

Mirza, M. R., Lund, B., Lindegaard, J. C., Keldsen, N., Mellemgaard, A., Christensen, R. D. & Bertelsen, K., 1 Oct 2010, In : Gynecologic Oncology. 119, p. 26-31 6 p.

Research output: Contribution to journalJournal articleResearchpeer-review

11 Citations (Scopus)
2006

Automated detection of a prostate Ni-Ti stent in electronic portal images.

Carl, J. H., Nielsen, H., Nielsen, J., Lund, B. & Larsen, E. H., 2006, In : Medical Physics. 33, 12, p. 4600-4605 6 p.

Research output: Contribution to journalJournal articleResearchpeer-review

Open Access
File
3 Citations (Scopus)
424 Downloads (Pure)

Feasibility study using a Ni-Ti stent and electronic portal imaging to localize the prostate during radiotherapy.

Carl, J. H., Lund, B., Larsen, E. H. & Nielsen, J., 2006, In : Radiotherapy and Oncology. 78, p. 199-206

Research output: Contribution to journalJournal articleResearchpeer-review

16 Citations (Scopus)
2005

Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: a prospective multicenter phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) comparing TCG with standard TC

Bois, A. D., Sehouli, J., Lund, B., Joly, E., Huober, J., Jensen, TS., Levy, E., Heilmann, V., Boman, K., Hardy-Bessard, AC., Burges, A., Maenpaa, J., Pujade-Lauraine, E., Pfisterer, J., Gropp, M., Staehle, A., Wimberger, P., Jackisch, C., Schmalfeldt, B., Belau, A. & 5 others, Loibl, S., Wollschlaeger, K., Canzler, U., Rochon, J. & GINE, GCIG. I. AGO-OVAR. NSGO., 1 Nov 2005, In : International Journal of Gynecological Cancer. 15, Suppl. 3, p. 224-225 2 p.

Research output: Contribution to journalJournal articleResearchpeer-review

5 Citations (Scopus)

The results of treatment of epithelial ovarian cancer after centralisation of primary surgery. Results from North Jutland, Denmark

Andersen, E. S., Knudsen, A., Svarrer, T., Lund, B., Nielsen, K., Grove, A. & Tetsche, M. S., 2005, In : Gynecologic Oncology. 99, 3, p. 552-556 5 p.

Research output: Contribution to journalJournal articleResearchpeer-review

26 Citations (Scopus)
2001

Multicenter phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer

Underhill, CR., Parnis, FX., Highley, MS., Ahern, J., Harper, PG., Hansen, H., Lund, B., Dombernowsky, P., Hirsch, F., Hansen, M., Carmichael, J. & Williams, H. C., 1 Sep 2001, In : Anti-Cancer Drugs. 12, 8, p. 647-652 6 p.

Research output: Contribution to journalJournal articleResearchpeer-review

12 Citations (Scopus)